The TREM2 agonistic antibody AL002 in early Alzheimer’s disease: a phase 2 randomized trial
Catherine J. Mummery, Arthur J. Mayorga, Adam Simmons, T.W. Chow, Brady Burgess, Tuan Nguyen, Jingjing Gao, Balasubrahmanyam Budda, Lovingly Quitania Park, Ruchi Gupta, Caiyan Li, Li Shi, Sara Kenkare-Mitra, Arnon Rosenthal, Robert Paul, Michael P. Ward, Derk D. Purcell, Stephen Salloway, Michael Grundman, Gary Romano, Giacomo Salvadore
Topics & Concepts
TREM2MedicinePlaceboClinical endpointInternal medicineRandomized controlled trialAntibodyAdverse effectPharmacodynamicsPharmacologyImmunologyClinical trialBlockadeReceptorPhases of clinical researchNuisance parameterMonoclonal antibodyDementiaEncephalopathyEndocrinologyConfidence intervalNeuroinflammation and Neurodegeneration MechanismsNeurological Disease Mechanisms and TreatmentsInflammation biomarkers and pathways